Wells Fargo’s ArriVent BioPharma AVBP Stock Holding History
Bought
Maintained
Sold
Other funds holding AVBP
IAM
Wells Fargo's AVBP Position: Q3 2026 in Review
Wells Fargo reduced its ArriVent BioPharma (AVBP) stake by 65% in Q3 2026, selling an estimated $729K and leaving 12,869 shares worth $390K. The position accounts for ﹤0.01% of the portfolio, ranked #4340.
Wells Fargo first reported a position in AVBP in Q1 2024 and has held it in 11 quarters since. The position peaked at $1.27M in Q2 2026. 153 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.
- Wells Fargo held 12,869 shares of ArriVent BioPharma worth $390K as of Q3 2026.
- Wells Fargo sold 23,801 ArriVent BioPharma shares in Q3 2026, an estimated $729K.
- ArriVent BioPharma made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #4340 holding.
- Wells Fargo first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 11 quarters since.
- Wells Fargo's ArriVent BioPharma position peaked at $1.27M in Q2 2026.
- 153 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.
Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.